頁籤選單縮合
題 名 | 日本のバイオテクノロジー産業と競争政策--リサーチツール特許のライセンス問題=日本之生物科技產業與競爭政策--Research Tool發明專利中的授權問題、Biotechnological Industries and the Competition Policy in Japan: Licensing Issues in Research Tool Patents |
---|---|
作 者 | 稗貫俊文; 趙珮怡; 劉曉倩; | 書刊名 | 清華科技法律與政策論叢 |
卷 期 | 2:2 民94.06 |
頁 次 | 頁7-53 |
分類號 | 440.6 |
關鍵詞 | 研究工具專利; 不可或缺之設施法理; 日本醫藥品產業; 為進行試驗或研究所採作之特許實施; Research tool patents; Essential facility doctrine; Japanese pharmaceutical industries; Compulsory licensing application for trial or research purpose; |
語 文 | 日文(Japanese);中文(Chinese) |
中文摘要 | 日本政府於1980年代後半開始採行強化智慧財產權制度之政策。2002年3月以「智慧財產立國」為目標,於內閣府設立「智慧財產戰略會議」,並於同年7月公佈「智慧財產戰略大綱」。本文認為專利戰略計畫關聯問題工作小組之「專利發明之靈活運用等相關問題」報告書,是乃象徵日本政府做出此積極性選擇之最新動向。此報告書關於研究工具專利之實施,嚴格地限定不構成侵害專利權之「試驗或研究」之容許範圍,同時亦不贊成緩和裁定實施權制度之運用基準。若此報告書可代表日本政府的立場的話,可說是日本政府有意對日本醫藥產業課以嚴格的試煉。本文認為,在面對智慧財產政策新階段之際,日本之競爭政策亦不應將不可或缺之設施(essential facility)法理導入智慧財產之領域中,以此去幫助無法承受國際競爭之醫藥企業之生存。 |
英文摘要 | In the late 1980s, the Japanese governmentbegan to strengthen its policies relating to intellectual property rights system. Observing the goal to lay the intellectual property rights as the bases for national development, in March 2003, "The Strategic Meeting on Intellectual Property" was held under the auspices of Cabinet; next came "The Strategic Guideline for Intellectual Property" of July. Besides, this article tends to believe that the "Report on Issues Related to the Flexible Application of Inventions" released by the "Working Group for Patent Strategic Plan Related Issues" indicates to us a new trend of Japanese government's positive attitude. However, in regard to the fair use exemption concerning the application for trail or research purposes, the Report took a strict limitation position. The Report also took the position against loosening the standard of compulsory licensing. Should this Report's wordings can be taken as the reflection of Japanese government's official position, it becomes unavoidable to take that the government intends to impose severe tests on the Japanese pharmaceutical industries. On the other hand, envisioning the incoming new stage of IP industrial policy, this article also suggests that the Japanese competition policies should not apply the essential facility doctrine to the field of the intellectual property in order to help pharmaceutical companies which can not bear international competitions. |
本系統中英文摘要資訊取自各篇刊載內容。